Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0684249 (
lung carcinoma
)
23,830
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
mRNA differential display was applied to three small cell
lung carcinoma
(SCLC) cell lines, six non-small cell
lung carcinoma
(NSCLC) cell lines, and three normal lung tissues to identify genes differentially expressed between
lung carcinoma
cells and normal lung tissues and between SCLC cells and NSCLC cells. We isolated five differentially expressed genes, two that were novel and three that were already known.
DIL-1
(differentially expressed in cancerous and noncancerous lung cells; HGMW-approved symbol SPON2) and pulmonary surfactant apoprotein A were expressed in normal lung tissues but not in
lung carcinoma
cell lines, whereas DIL-2 (HGMW-approved symbol C20orf2) and nm23-H1 were expressed in
lung carcinoma
cell lines but not in normal lung tissues. The remaining gene, Annexin II, was expressed at a lower level in SCLC than in NSCLC and normal lung tissues. These genes were also differentially expressed in primary lung cancers. One of the two novel genes,
DIL-1
, encodes a secreted protein homologous to the Mindin/F-spondin family. The other, DIL-2, encodes a protein with a putative ATP/GTP binding site motif. These data provide basic information necessary to understand the differences in gene expression profiles between
lung carcinoma
and normal lung and between SCLC and NSCLC. Further characterization of these genes will help to clarify the molecular mechanisms of human lung carcinogenesis.
...
PMID:Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. 1051 75